William Blair upgraded Allakos to Outperform from Market Perform ahead of two lirentelimab readouts that are due either by year-end or early 2024, including a Phase 2 study readout in atopic dermatitis and a Phase 2b readout in chronic spontaneous urticaria. The company “has a new chance in these dermatology indications” and the firm believes lirentelimab has “a strong chance” of showing efficacy in these two readouts, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALLK:
